SPEGRA TABLET

SPEGRA TABLET

Spegra Tablets is a combination of Dolutegravir, emtricitabine, and tenofovir alafenamide tablets are determined for use apart as a through regimen for the medication of human immunodeficiency virus type 1 (HIV-1) infection. Spegra Tablets is a used to treatment of antiretroviral drug. Dolutegravir is post-exposure prophylaxis. Emtricitabine & Tenofovir alafenamide is a nucleotide reverse transcriptase inhibitor for the medication of chronic hepatitis B virus (HBV) disease.

Mechanism of Action:

Spegra Tablets is an HIV-1 antiviral agent. Emtricitabine is a cytidine mate which, when phosphorylated to emtricitabine 5'-triphosphate plays with deoxycytidine 5'-triphosphate for HIV-1 reverse transcriptase. Tenofovir alafenamide presents a 91% lower plasma combination with an intracellular existence of about 20-fold higher when compared to tenofovir disoproxil. Tenofovir alafenamide grows more in peripheral blood mononuclear cells related to red blood cells. Dolutegravir prevents HIV integrase by required to the active site and blocking the string transfer step of retroviral DNA unification in the host cell. As HIV-1 reverse transcriptase combines emtricitabine into producing DNA strands, new nucleotides are incapable to be integrated, leading to viral DNA chain termination. TAF is mostly metabolized intracellular to TFV.

Pharmacokinetics

1.Absorption

When 50 mg of Dolutegravir once daily was orally conduct to HIV-1 contaminate adults, the AUC, Cmax, and Cmin is 53.6 mcg h/mL, 3.67mcg/mL, and 1.11mcg/mL, commonly. Emtricitabine attains a Cmax of 1.8±0.7µg/mL with a Tmax of 1-2 hours and has an AUC of 10±3.1µg*hr/mL. Tenofovir alafenamide produces a lipophilic group that masks the weak charge of the person moiety which increases its oral bioavailability.

2. Distribution

The organization of a dose of 50 mg of Dolutegravir presents a supposed volume of distribution of 17.4 L.The probable central volume of distribution is 42.3L and the incidental The volume of distribution is 55.4L. The volume of distribution of tenofovir alafenamide was higher than 100 L.

3. Metabolism

Dolutegravir is greatly metabolized over three main pathways and it forms no long-lived metabolites. The first pathway is described by the glucuronidation by UGT1A1, the second pathway by carbon oxidation by CYP3A4 and the third pathway is what develops to be a subsequent oxidative defluorination and glutathione combination. Emtricitabine is almost 86% unmetabolized. Tenofovir alafenamide presents important plasma stability and hence, its activation is implementing inside the mark cells.

4. Excretion

Dolutegravir is given almost all total doses is found in a proportion of 53% excreted unaffected in the feces and 31% excreted in the urine. Emtricitabine is 86% regained reclaimed in the urine and 14% recovered in feces.

Contraindication:

Spegra Tablets are contraindicated in patients with former hypersensitivity response to Dolutegravir. The taking dofetilide immunity to the possible for raised dofetilide plasma concentrations and the uncertainty for severe and growth-dangerous actions.

Drug Interaction:

The Suggested dose of Spegra Tablets is one tablet taken orally once daily with or without food. The pediatric patients weighing at least 40 kg (88 lbs.) and creatinine approval were greater than or equal to 30 mL per minute. Spegra Tablets is not suggested in patients with estimated creatinine go-head below 30 mL per minute

Side-Effects:

Nausea, Fatigue Abdominal pain, Vomiting, Anemia decreased platelet count, increased serum creatinin, Diarrhea, Upper respiratory tract infection.

Storage:

Store below 30°C (86°F). Secure from humidity. Distribute only in the original bottle.

Pregnancy & lactation

Spegra Tablets should be used during pregnancy only if the potentiality advantage maintains the potential risk. Breastfeeding is not suggested due to the potential for HIV transmission.

Contact details
Apple Pharmaceuticals
Mobile/Viber/Telegram :+919987711567
WeChat : applepharmaceuticals
Skype : applepharma
qq : 2097734872
Email id :applepharmaceutical@gmail.com
Website : https://myapplepharma.com/